SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through extraordinary times; markets are in turmoil and uncertainty is part of many businesses and industries. It turns out that the pharma industry has been relatively immune to the economic downturn, because illness doesn't take a vacation.
During the midst of the difficult times this year, the pharmaceutical giant Johnson & Johnson inaugurated an R&D center in Shanghai, the largest of its kind in Asia. A similar plan was laid down by its biotech counterpart Genzyme, who invested USD90 million in Beijing to construct the company's first ever research facility in Asia.
What has made pharma and biotech companies invest heavily in Asia?
Find out the answer at Asia Pharma R&D Leaders 2010. As the time is drawing near for the event, the world's industry leaders will be under one roof to provide solutions and case studies in the challenging areas of drug research and development.
This year's meeting will aim to improve understanding of how the Asian pharmaceutical market is changing. Meet with key pharma industry leaders to discuss and learn from their own experiences and hear from real-life case studies on operational, regulatory, and strategic challenges of outsourcing drug discovery work to Asia. This event also provides excellent networking opportunities by way of a speed networking sessions where attendees will exchange details and make new contacts, as well as our contact system, which will allow participants to arrange meetings and email conference with attendees, speakers and the press.
An updated list of this year's highlighted topics: -- Partnering for innovation in Asia, new collaboration opportunities with big pharma Laurent Bertin, Vice President, R&D External Innovation, Sanofi-Aventis Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche Daniel Grant, Head of Strategic Alliances, Pfizer Australia Pierre Desmons, Director, Head of Development Partnerships, GlaxoSmithKline Biologicals -- Regulatory updates in China and how the FDA is verifying the quality of outsourced work Christopher Hickey, Country Director (China), U.S. Food and Drug Administration -- Successful stories of R&D operation management in Asia and Do's & Don'ts in outsourcing Steve Yang, Head of Research Asia Global R&D, Pfizer Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia, Johnson & Johnson Li Chen, Chief Scientific Officer Roche R&D China, Roche Tony Zhang, Managing Director and Site Head of China, Eli Lilly Global R&D Canwen Jiang, Head of R&D Asia, Genzyme Corporation Kim Andersen, Vice President R&D, Lundbeck AS Samantha Du, CEO, Hutchison MediPharma Richard Wang, Director, Strategic Alliance and Collaboration for Asia, AstraZeneca Yoshiki Nishikawa, Director of Kobe Pharma Research Institute Nippon, Boehringer Ingelheim
Plus, the event sets up an effective platform for attendees to meet face to face with a variety of Asia's local CROs and leading clinical practitioners to discuss the specifics of outsourcing requirements.
An international audience consisting of senior-level pharma and biotech executives from the R&D, clinical development, business development, global market access, licensing, and regulatory affairs functions will be in attendance. For the full program and list of companies scheduled to attend, please visit the event website at http://www.aprdl.com.
For more information on registration and sponsoring/exhibiting, please contact: Daniel Chen Global Leaders Institute Phone: +86-21-3251-6046 Email: firstname.lastname@example.org
SOURCE Global Leaders Institute
|SOURCE Global Leaders Institute|
Copyright©2009 PR Newswire.
All rights reserved